Preventive and remedial application of etanercept attenuate monocrotaline-induced pulmonary arterial hypertension

Heart failure and anti tumor necrosis factor-alpha in systemic chronic inflammatory diseases

(2013) Emanuele Sinagra et al.   European Journal of Internal Medicine

Therapeutic Potential of Tumour Necrosis Factor-alpha Antagonists in Patients with Chronic Heart Failure

(2013) Qamar Javed et al.   Heart Lung and Circulation

Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial

(2013) Josef S Smolen et al.   LANCET

Off-Label Uses of Anti-TNF Therapy in Three Frequent Disorders: Behçet’s Disease, Sarcoidosis, and Noninfectious Uveitis

(2013) Daniel Sánchez-Cano et al.   MEDIATORS OF INFLAMMATION

Monocrotaline-induced pulmonary arterial hypertension is attenuated by TNF-α antagonists via the suppression of TNF-α expression and NF-κB pathway in rats

(2012) Qiang Wang et al.   VASCULAR PHARMACOLOGY

The monocrotaline model of pulmonary hypertension in perspective

(2011) Jose G. Gomez-Arroyo et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

Linking new and old concepts: inflammation meets the Warburg phenomenon in pulmonary arterial hypertension

(2011) Todd M. Kolb et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Inflammation, Growth Factors, and Pulmonary Vascular Remodeling

(2009) Paul M. Hassoun et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: Results of a multicenter, randomized, double‐blind, active drug–controlled study

(2008) Michael E. Weinblatt et al.   ARTHRITIS AND RHEUMATISM

Infliximab Treatment in a Patient with Systemic Sclerosis Associated with Lung Fibrosis and Pulmonary Hypertension

(2005) Elena Bargagli et al.   RESPIRATION